目的 探討咳露口服液聯(lián)合酮替芬治療咳嗽變異性哮喘的臨床療效和安全性。方法 選取2016年11月—2017年11月于洛陽市中心醫(yī)院就診的咳嗽變異性哮喘患者120例，隨機分成對照組和治療組，每組各60例。對照組口服富馬酸酮替芬片，1片/次，2次/d；治療組患者在對照組的基礎(chǔ)上口服咳露口服液，15 mL/次，3次/d。兩組患者均連續(xù)治療2個月。觀察兩組患者臨床療效，同時比較治療前后兩組患者哮喘控制測試（ACT）評分、日常生活活動（ADL）評分、咳嗽癥狀積分、嗜酸性粒細(xì)胞（EOS）絕對值、肺功能和不良反應(yīng)。結(jié)果 治療后，對照組和治療組臨床有效率分別為81.67%和95.00%，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組患者ACT和ADL評分顯著升高（P<0.05），咳嗽癥狀積分顯著降低（P<0.05），且治療組患者ACT、ADL及咳嗽癥狀積分水平明顯好于對照組（P<0.05）。治療后，兩組EOS絕對值顯著降低（P<0.05），肺功能指標(biāo)用力肺活量（FVC）和第1秒鐘用力呼吸容積（FEV1）顯著升高（P<0.05），且治療組患者EOS絕對值及肺功能較對照組患者改善更明顯（P<0.05）。治療期間，治療組患者不良反應(yīng)發(fā)生率為3.33%，顯著低于對照組的15.00%，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 咳露口服液聯(lián)合酮替芬治療咳嗽變異性哮喘療效顯著，安全性好，具有一定的臨床推廣應(yīng)用價值。

Objective To investigate the clinical efficacy and safety of Kelu Oral Liquid combined with ketotifen in treatment of cough variant asthma. Methods Patients (120 cases) with cough variant asthma in Luoyang Central Hospital from November 2016 to November 2017 were randomly divided into control and treatment groups, and each group had 60 cases. Patients in the control group were po administered with Ketotifen Fumarate Tablets, 1 tablet/time, twice daily. Patients in the treatment group were po administered with Kelu Oral Liquid on the basis of the control group, 15 mL/time, three times daily. Patients in two groups were treated for 2 months. After treatment, the clinical efficacy was evaluated, and ACT, ADL and cough symptom scores, absolute value of EOS, lung function and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups was 81.67% and 95.00%, respectively, and there were differences between two groups (P<0.05). After treatment, the ACT and ADL scores in two groups were significantly increased (P<0.05), but cough symptom scores were significantly decreased (P<0.05), and the ACT, ADL and cough symptom scores in the treatment group were significantly better than those in the control group (P<0.05). After treatment, the absolute value of EOS in two groups was significantly decreased (P<0.05), but FVC and FEV1 levels were significantly increased (P<0.05), and the absolute value of EOS, lung function in the treatment group was significantly better than that in the control group (P<0.05). During the treatment, the adverse reactions rate in the treatment group was 3.33%, which was significantly lower than 15.00% in the control group, with significant difference between two groups (P<0.05). Conclusion Kelu Oral Liquid combined with ketotifen has significant curative effect in treatment of cough variant asthma with good safety, which has a certain clinical application value.